- Home
- COLL vs INVA Comparison
COLL vs INVA Comparison
Compare COLL & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- INVA
- Stock Information
- Founded
- COLL 2002
- INVA 1996
- Country
- COLL United States
- INVA United States
- Employees
- COLL N/A
- INVA N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- COLL Health Care
- INVA Health Care
- Exchange
- COLL Nasdaq
- INVA Nasdaq
- Market Cap
- COLL 1.1B
- INVA 1.1B
- IPO Year
- COLL 2015
- INVA 2004
- Fundamental
- Price
- COLL $45.49
- INVA $22.17
- Analyst Decision
- COLL Strong Buy
- INVA Buy
- Analyst Count
- COLL 5
- INVA 5
- Target Price
- COLL $45.40
- INVA $36.60
- AVG Volume (30 Days)
- COLL 520.4K
- INVA 905.8K
- Earning Date
- COLL 11-06-2025
- INVA 11-05-2025
- Dividend Yield
- COLL N/A
- INVA N/A
- EPS Growth
- COLL N/A
- INVA 53.96
- EPS
- COLL 1.63
- INVA 1.52
- Revenue
- COLL $757,067,000.00
- INVA $388,521,000.00
- Revenue This Year
- COLL $21.41
- INVA $7.98
- Revenue Next Year
- COLL $3.28
- INVA $11.60
- P/E Ratio
- COLL $28.29
- INVA $14.41
- Revenue Growth
- COLL 26.34
- INVA 10.14
- 52 Week Low
- COLL $23.23
- INVA $16.52
- 52 Week High
- COLL $48.18
- INVA $22.76
- Technical
- Relative Strength Index (RSI)
- COLL 74.50
- INVA 79.34
- Support Level
- COLL $35.26
- INVA $21.81
- Resistance Level
- COLL $48.18
- INVA $22.76
- Average True Range (ATR)
- COLL 1.74
- INVA 0.71
- MACD
- COLL 0.93
- INVA 0.42
- Stochastic Oscillator
- COLL 80.20
- INVA 88.51
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.